Page 855 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 833

Oropharyngeal cancer, 432 Pain (Continued) Papillomavirus, 19–21
Orthovoltage radiation, carcinogenesis from, behavior changes, 288, 290t in cats, 21–22
215
viral plaques/fibropapillomas, 353
clinical metrology instruments in,
VetBooks.ir Orthovoltage x-ray, 215 palpation, 288 in dogs, 19–21
288–289, 291t
polymerase chain reaction and, 353
Osteoblast, alkaline phosphatase and, 129
Osteocartilaginous tumor, 505 physical examination in, 288 prevalence of, 356
Osteoid, 130 quantitative sensory testing in, 290 replication of, 352
Osteomas, 448, 552 staff/owner involvement in, 288–289 squamous cell carcinoma and, 353
characteristics of, 140 levels of, 288–289 Papovaviridae, 19
Osteosarcoma, 18–19 neurobiologic signature of, 297 Paracetamol (acetaminophen), 292t
characteristics of, 140 tumors associated with, 287t Paragangliomas, 573
cytoreductive surgery for, 169 Pain management, 286 Paranasal sinuses, tumor of, 504
ezrin expression and, 51 acupuncture for, 298 Paraneoplastic syndrome (PNS),
fine-needle aspiration of, 140f analgesics for, 292t 98–112, 463
incidence rates of, 85 approaches to, 288 causes of, 98
neutering/spaying and, 92 drugs and strategies for definition of, 98
of oral cavity, 435 acetaminophen, 295 tumors associated with, 99b
prognosis of, 444 anticonvulsant drugs, 296 weight loss and, 98
sex hormones and, 92 bisphosphonate, 297 Parathyroid adenomas, 581
in spinal cord, 666t N-methyl-D-aspartate antagonist, Parathyroid hormone-related protein
Ovarian adenocarcinoma, 598 295–296 (PTHrP), 632
Ovarian cancer, 50 NSAIDs, 290–295 hypercalcemia of malignancy and, 100
Ovarian seminomas, 598 opioids, 295 tumor-associated, 100
Ovarian-steroid tumor, 598 sodium channel blockade, 296 Parathyroid tumors, 580–582
Ovarian tumor, 597–600 steroids, 296–297 characteristics of, 137
comparative aspects of, 599–600 tramadol, 295 Parenchymal cell, 62
diagnostic techniques and workup for, 599, tricyclic antidepressants, 296 Parenteral nutrition
599f glucocorticoid for, 296–297 formulation for, 305–306
incidence of, 597 importance of, 288 form for, 306f–307f
ovariohysterectomy for, 599 pharmacologic desensitization strategy for, preparation of, 306
pathology and natural behavior of, 597–598 298 glucose and lipid proportions in, 306
canine ovarian tumors, 597–598 pharmacologic therapy as, 290–297 high protein/high calorie products, 305t
feline ovarian tumors, 598 radiation therapy for, 297–298 substrates for, 305–306
prognosis for, 599 Pain syndrome, 296 types and complications of, 305
therapy for, 599 Palliative care PARG. see Poly adenosine diphosphate ribose
Ovariohysterectomy (OHE) for intracranial tumors, 662, 663f glycohydrolase
hyperadrenocorticism after, 598 transitioning to, 317 Parosteal osteosarcoma, 550, 550f
mass at uterine stump after, 600f Palliative chemotherapy, 183 PARP. see Poly adenosine diphosphate ribose
ovarian tumors and, 599 Palliative radiation therapy, 215 polymerase
Oxygen, irradiation and, 210 for primary and metastatic bone cancer Partial pancreatectomy, for canine insulinoma,
Oxygen cycle, DNA synthesis and, 210 pain, 547 583–584
Oxygen depletion, 37–38 Palliative surgery, considerations for, Partial parenteral nutrition (PPN), 305
168–169 formulation sheet for, 307f
P Pamidronate, 292t Particle bombardment, 252t
p21, 39 Pancreatic beta-cell tumors, 582–584 Partnership, in patient care, 314
canine osteosarcoma and, 525 in cats, 584 Pasireotide, for canine pituitary-dependent
p53, 37–38, 43–44 in dogs, 582–584 hypercortisolism, 567
canine osteosarcoma and, 525 Pancreatic carcinoma, 105 Passive diffusion, chemotherapeutic agent
cell cycle control and, 38f, 41f Pancytopenia, 629 uptake and, 184
expression, 39 Papanicolaou staining, 128–129 Paternalism, 311
feline cutaneous SCC and, 354 Papilloma Pathology laboratory, categories of errors at,
gene therapy and, 254 clinical features of 75
as genomic guardian, 38 in cats, 22 Patient-reported outcomes (PROs), 288
testicular tumors and, 628 in dogs, 20 PBMC. see Peripheral blood mononuclear cell
Paclitaxel, 185 development of PCNA. see Proliferating cell nuclear antigen
clinical use of, 195 in cats, 21–22 PCR. see Polymerase chain reaction
pharmacology of, 195 in dogs, 19–21 PCR-based techniques, detection of mutations
PAE. see Prostatic artery embolization diagnosis of, 22 and novel genes and assessment of
Pain treatment of, 22 clonality, 147–151
assessment of Papillomatosis PCR for antigen receptor rearrangement
activity in, 289–290 treatment of, 21 (PARR) assay, 150
approaches to, 289f types and clinical features of, 20 application of, 150–151